Logo Logo

Multiple sclerosis patients can benefit from expanded services from MSAA

  1. Home
  2. Partners
  3. Multiple sclerosis patients can benefit from expanded services from MSAA
Jun 04,2020

Multiple sclerosis patients can benefit from expanded services from MSAA

Partners

In light of the COVID-19 pandemic and its impact on the MS community, please know the Multiple Sclerosis Association of American (MSAA) has implemented several new programmatic changes to increase our availability and support to MS patients and their families across the country. These include:

  • Expanded hours to our toll-free Helpline (800-532-7667) which is staffed by trained and experienced social workers from 8:30 am to 8 pm Eastern, Monday through Friday
  • An online MRI Access Fund application form which also allows for the easy upload of required documents including the MRI order for a cranial or c-spine scan
  •  A COVID-19 hardship waiver to our Cooling, Equipment, and MRI programs for families in financial crisis
  •  Live online webinars to replace our scheduled in-person educational programs with topics addressing wellness care, newly diagnosed, minority populations, etc.

To learn more about these programs and ways MSAA can assist your MS patients, please visit our website at www.MyMSAA.org, or call (800) 532-7667. Thank you for all you do to care and support the MS community! Please stay safe and take care!

...125
0
Elizabeth Porco

Related Posts
Sep 04,2025
Dr. Kristen Krysko Wins 2025 Rachel Horne Prize For Women’s Research In Multiple Sclerosis
MS Community, Partners
Oct 11,2023
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
INforMS, Partners
Jul 24,2023
Is it MS or Something Else? updated guide is published to expedite and uncover the answer
Partners
Jul 17,2023
Positive Phase III results for Genentech’s Ocrevus (ocrelizumab)
INforMS, Partners
Apr 28,2023
NeurologyLive® and CMSC announce Giants of Multiple Sclerosis® 2023 class of inductees
CMSC PR, Partners
Mar 03,2023
Multiple sclerosis discovery could end disease’s chronic inflammation
Partners
Mar 03,2023
Congratulations to Dr. Carrie Hersh for her recent publication on DMTs
Partners
Mar 03,2023
The launch of the ROADMAP tool on Rare Disease Day 2023
MS Community, Partners
Feb 14,2023
Meghan Beier recently joined the Rowan Center for Behavioral Health
Partners
Jan 11,2023
Helius launches UpScript telehealth e-commerce site
INforMS, Partners
Dec 12,2022
A new patient assistance offering from Janssen
Partners
Oct 19,2022
Genentech to present new Ocrevus (ocrelizumab) data in multiple sclerosis & NMOSD research at ECTRIMS
INforMS, Partners
Aug 16,2022
US FDA – Ocrevus prescribing information to include warnings for Colitis and PML
INforMS, Partners
Apr 21,2022
Janssen Pharmaceuticals U.S. transparency report
INforMS, Partners
Mar 29,2022
Genentech premiers #MSVisibility 2022
INforMS, Partners
Mar 15,2022
Sanofi’s 2022 annual pricing principles report
INforMS, Partners
Feb 01,2022
MR epectroscopic imaging may help better diagnose, treat multiple sclerosis
Partners
Oct 01,2021
Ublituximab, potential relapsing multiple sclerosis therapy, up for FDA approval
INforMS, Partners
Sep 30,2021
NeurologyLive® announces the inaugural Giants of Multiple Sclerosis™ Program
CMSC PR, Partners
Sep 22,2021
The Brain Under Siege by Dr. Howard Weiner
MS Community, Partners
Jun 24,2021
Introducing Atara Biotherapeutics: the role of EBV in multiple sclerosis and the Phase II EMBOLD study
INforMS, Partners
Jun 15,2021
MRI in Multiple Sclerosis Guidelines Update: North America, Europe align on new recommendations
Partners
Jun 10,2021
Congratulations to Dr. Robert Lisak: recipient of ANA’s Distinguished Neurology Teacher Award
MS Community, Partners
May 07,2021
Study on cognitive processing speed changes in RMS subjects treated with Ozanimod
INforMS, Partners
Apr 16,2021
New data for Ocrevus disease progression (ocrelizumab) reinforce significant slowing
INforMS, Partners
Apr 07,2021
New Genentech data at 2021 AAN highlight impact & breadth of neuroscience portfolio
INforMS, Partners
Mar 19,2021
Janssen announces U.S. FDA approval of PONVORY™ (ponesimod)
INforMS, Partners
Mar 08,2021
NeurologyLive® & the CMSC launches MS Cure Connections® Video Series
CMSC PR, Partners
Feb 02,2021
FDA approval of intramuscular Plegridy (Peginterferon beta-1a)
INforMS, Partners
Aug 24,2020
Genentech’s enspryng for Neuromyelitis Optica Spectrum Disorder
INforMS, Partners
Aug 19,2020
Mylan brings critical access to the multiple sclerosis community
INforMS, MS Community, Partners
Jul 08,2020
WHO and AMA statement
Advocacy, CMSC PR, MS Community, Partners
Jul 01,2020
A letter from Lemtrada regarding its home phlebotomy partner, EMSI
INforMS, Partners
Jun 01,2020
ZEPOSIA launch press release
Partners
May 27,2020
Rebif® U.S. label includes pregnancy outcomes & lactation information
INforMS, Partners
Apr 27,2020
New 6-year data for Genentech’s Ocrevus (ocrelizumab) findings
Partners
Apr 02,2020
Coronavirus and multiple sclerosis reporting database
CMSC PR, Partners
Mar 26,2020
FDA approves Zeposia (Ozanimod), oral therapy for all with relapsing multiple sclerosis
INforMS, Partners
Mar 10,2020
CMSC update on COVID-19: NMSS National Medical Advisory Committee recommendations
CMSC PR, Partners
Mar 03,2020
Multiple sclerosis and COVID-19 registry
CMSC PR, Partners
Feb 27,2020
Please read: Coronavirus and multiple sclerosis statement
Partners
Dec 01,2019
Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum
INforMS, Partners
Nov 26,2019
NeurologyLive™ adds CMSC to its Strategic Alliance Partnership program
INforMS, Partners
Sep 17,2019
EMD Serono initiates pivotal Phase III program for investigational Evobrutinib in RMS
INforMS, Partners
Sep 12,2019
Genentech presents new six-year Ocrevus (Ocrelizumab) data
INforMS, Partners
Sep 11,2019
Genentech’s Satralizumab significantly reduced relapse risk
INforMS, Partners
Sep 09,2019
Genentech presents new Ocrevus (Ocrelizumab) biomarker data
INforMS, Partners
Sep 03,2019
Press release – Genentech to present piviotal data at ECTRIMS
INforMS, Partners
Aug 07,2019
Rutgers Health leading program to support multiple sclerosis children
INforMS, Partners
Jul 18,2019
Dr. Anne Cross discusses strides In multiple sclerosis research, recent award
INforMS, Partners
Jul 16,2019
EMD Serono’s embracing carers launches ‘Time Counts’ to raise 1M minutes of support
INforMS, Partners
Jul 15,2019
CMSC opens weeklong mental health program to help mentor and train multiple sclerosis specialists
CMSC PR, Partners
Jun 28,2019
Alexion’s Soliris gets new, and lucrative, rare disease indication
INforMS, Partners
Jun 24,2019
CMSC, multiple sclerosis non-profits and Polar Products recognizes over twenty years of progress
CMSC PR, Partners
Jun 13,2019
Lenox Hill Hospital multiple sclerosis support group
Partners
May 08,2019
Genentech presenting new Ocrevus (Ocrelizumab) data at AAN Meeting
INforMS, Partners
May 02,2019
MSAA recognizes ten years of artwork from individuals with multiple sclerosis
INforMS, MS Community, Partners
Apr 19,2019
OHSU doctors part of ‘breakthrough’ research on treating multiple sclerosis
INforMS, Partners
Apr 15,2019
Anne Cross, neurologist with pioneering work into B-cells/multiple sclerosis, awarded John Dystel Prize
INforMS, Partners
Mar 29,2019
Novartis gets FDA approval for Mayzent (Siponimod), the first oral drug to treat SPMS
INforMS, Partners
Mar 27,2019
Novartis receives FDA approval for MAYZENT (Siponimod)
INforMS, Partners
Oct 11,2018
TG Therapeutics, Inc. announces final phase 2 multiple sclerosis data presentation at ECTRIMS
INforMS, Partners
Oct 10,2018
Novartis announces FDA filing acceptance of Siponimod (BAF312)
INforMS, Partners
Oct 10,2018
New efficacy and safety data on multiple sclerosis portfolio to be presented
INforMS, Partners
Oct 10,2018
Press release – Ocrevus data show early initiation reduces progression
INforMS, Partners
Sep 12,2018
Novartis announces PARADIGMS study demonstrating benefit of Gilenya®
INforMS, Partners
Aug 13,2018
Call for test sites: using patient-reported outcomes to drive multiple sclerosis care
Partners
Jun 14,2018
Genentech announces new Ocrevus (Ocrelizumab) data for PPMS
INforMS, Partners
May 01,2018
TREAT-MS
CMSC PR, Partners
Apr 25,2018
New Ocrevus (Ocrelizumab) data demonstrate reductions In activity & progression In RMS
INforMS, Partners
Apr 18,2018
Imagerywork
Partners
Mar 23,2018
Phase III data in the lancet show Novartis outcomes in secondary progressive multiple sclerosis
INforMS, Partners
Mar 05,2018
Abbvie and Biogen pull multiple sclerosis drug Zinbryta following urgent EMA safety review
INforMS, Partners
Jan 13,2018
CVS/Aetna combo a formidable pharma rival when it comes to access
INforMS, Partners
Dec 04,2017
National Multiple Sclerosis Society endorses multiple sclerosis “NARCRMS” data registry
CMSC PR, INforMS, Partners
Dec 01,2017
Mayo Clinic develops test to distinguish other demyelinating diseases from multiple sclerosis
INforMS, Partners
Aug 28,2017
International Journal of Multiple Sclerosis Care wins 2017 APEX Award
CMSC PR, Partners
Jul 11,2017
OMRF multiple sclerosis center wins top multiple sclerosis research award
INforMS, Partners
Jun 14,2017
Research sheds light on who’s multiple sclerosis could worsen
INforMS, MS Community, Partners
May 30,2017
Bayer receives FDA approval of myBETAapp™ and BETACONNECT Navigator™
MS Community, Partners
May 30,2017
CMSC 2017 Annual Meeting – Celgene’s investigational therapy Ozanimod safe, effective in treating RMS
CMSC PR, Partners
May 30,2017
CMSC 2017 Annual Meeting – Rituxan-treated multiple sclerosis patients three times more likely to have improved brain scans
CMSC PR, Partners
May 30,2017
CMSC 2017 Annual Meeting – review suggests certain multiple sclerosis patient groups may discontinue DMTs
CMSC PR, Partners
May 26,2017
CMSC 2017 Annual Meeting – Tysabri improves mental outlook for patients with secondary progressive MS
CMSC PR, Partners
May 26,2017
CMSC 2017 Annual Meeting – multiple sclerosis patients should contribute to outcome measure development, study argues
CMSC PR, Partners
May 26,2017
CMSC 2017 Annual Meeting – single session of ball-throwing exercise improves balance control in multiple sclerosis
CMSC PR, Partners
May 26,2017
CMSC 2017 Annual Meeting – Genentech starts site to connect multiple sclerosis patients and caregivers with resources
CMSC PR, Partners
May 18,2017
CMSC 2017 Annual Meeting – all about teamwork in multiple sclerosis
CMSC PR, Partners
May 10,2017
The hidden costs of multiple sclerosis
INforMS, Partners
May 09,2017
David Sackett trial of the year awarded to the Oratorio Study
MS Community, Partners
May 01,2017
CMSC 2017 Annual Meeting – experts to focus on multiple sclerosis patient care at CMSC Annual Meeting in New Orleans
CMSC PR, Partners
Apr 29,2017
Biogen Idec to present new two-year data from the PLEGRIDY phase 3 advance study
INforMS, Partners
Dec 15,2016
Ari Waisman receives most prestigious European prize for multiple sclerosis research
Partners
Oct 12,2016
United Spinal Association offering range of materials at exhibit booth at CMSC 2016 Annual Meeting
CMSC PR, Partners
Jul 19,2016
Multiple sclerosis rehabilitation specialist, Susan Bennett, receives CMSC Lifetime Achievement Award
CMSC PR, Partners
Jul 06,2016
ICER draft report evaluating therapies for RRMS now open for public comment
INforMS, Partners
Jun 17,2016
CMSC 2016 Annual Meeting – Clay Walker’s concert at the CMSC 30th anniversary celebration
CMSC PR, Partners
Jun 16,2016
How does menopause affect women with multiple sclerosis?
INforMS, MS Community, Partners
Jun 15,2016
CMSC 2016 Annual Meeting – Multiple Sclerosis News Today’s exclusive interview with Mark Freedman
CMSC PR, Partners
Jun 13,2016
CMSC 2016 Annual Meeting – Multiple Sclerosis News Today’s exclusive interview with Summer Kernan
CMSC PR, Partners
Jun 09,2016
Nine CMSC 2016 Annual Meeting exclusive interviews you can’t miss
CMSC PR, Partners
Jun 07,2016
CMSC 2016 Annual Meeting – Fingolimod (Gilenya) offers consistent health benefits in RRMS patients
CMSC PR, Partners
Jun 07,2016
CMSC 2016 Annual Meeting – multiple sclerosis patients, physical therapists have distinct decision-making processes
CMSC PR, Partners
Jun 07,2016
CMSC 2016 Annual Meeting – multiple sclerosis duration and disability level variously impacts arm function
CMSC PR, Partners
Jun 06,2016
CMSC 2016 Annual Meeting – multiple sclerosis and yoga: author and instructor says ancient discipline can help patients
CMSC PR, Partners
Jun 06,2016
CMSC 2016 Annual Meeting – Ocrevus (Ocrelizumab) in PPMS prevented disability progression
CMSC PR, Partners
Jun 03,2016
CMSC 2016 Annual Meeting – medical affairs vice president at EMD Serono discusses multiple sclerosis drug rebif, Multiple Sclerosis LifeLines
CMSC PR, Partners
May 24,2016
CMSC congratulates Kessler Foundation for this prestigious recognition
CMSC PR, Partners
May 16,2016
Dr. Ellen Mowry, in Interview, talks of clinical studies for Vitamin D & multiple sclerosis
CMSC PR, Partners
May 09,2016
High glutamate levels in brain seen to drive multiple sclerosis progression
CMSC PR, Partners
Apr 12,2016
New data from three Phase III studies of the medicine OCREVUS™ (ocrelizumab)
Partners
Jan 05,2016
Francois Bethoux, MD, named medical director of the Arts & Medicine Institute
Partners
Dec 26,2015
National Multiple Sclerosis Society honors physician
Partners
Dec 20,2015
MedDay misses endpoint in phase III multiple sclerosis vision loss trial
INforMS, Partners
Oct 21,2015
Biogen reports top-line results from phase 3 study evaluating Natalizumab in SPMS
INforMS, Partners
Oct 12,2015
EMD Serono announces publication of PRISMS-15 year follow-up study using Rebif in RRMS
INforMS, Partners
Oct 08,2015
Treatment effects maintained over 5 years in patients with RRMS who received Lemtrada
INforMS, Partners
Oct 08,2015
Genentech’s Ocrelizumab show positive pivotal study results in both RRMS and PPMS
INforMS, Partners
Oct 08,2015
EMD Serono announces recipients of the third annual €1 million grant for multiple sclerosis innovation
INforMS, Partners
Oct 07,2015
New analysis suggests Aubagio slows brain atrophy in people with Relapsing MS
INforMS, Partners
Oct 07,2015
Data show effects of TECFIDERA in newly-diagnosed and early disease course multiple sclerosis patients
INforMS, Partners
Oct 05,2015
Genzyme introduces “vs.MS”, a global initiative
INforMS, MS Community, Partners
Sep 27,2015
Genentech’s Ocrelizumab to show efficacy in people with PPMS in large phase III study
INforMS, Partners
Sep 25,2015
Bayer receives FDA approval for BETACONNECT
INforMS, Partners
Aug 21,2015
Novartis acquires all remaining rights to GSK Ofatumumab to develop treatments for multiple sclerosis
INforMS, Partners
Aug 09,2015
EMD Serono and Opexa amend agreement to support ongoing development of Tcelna for multiple sclerosis
INforMS, Partners
Jul 10,2015
Multiple Sclerosis Coalition applauds passage of 21st Century Cures Act
MS Community, Partners
Jun 29,2015
Genentech’s Ocrelizumab reduced both relapses and disability progression versus Rebif
INforMS, Partners
Jun 22,2015
Multiple Sclerosis Coalition announces new board President
CMSC PR, Partners
Jun 18,2015
Sandoz announces US launch of Glatopa, the first generic competitor to Copaxone 20mg
INforMS, Partners
Jun 09,2015
Novartis statement on reported case of PML
INforMS, Partners
Apr 29,2015
FDA accepts biologics license application for ZINBRYTA for treatment of multiple sclerosis
INforMS, Partners
Apr 24,2015
Mallinckrodt research fellowship award program announcement
INforMS, Partners
Apr 22,2015
FDA accepts filing of BETACONNECT for RRMS patients taking BETASERON
INforMS, Partners
Apr 21,2015
International survey identifies opportunities for improving multiple sclerosis treatment satisfaction
INforMS, MS Community, Partners
Apr 20,2015
TECFIDERA Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
INforMS, Partners
Mar 27,2015
EMA validates marketing authorization application for ZINBRYTA for treatment of multiple sclerosis
INforMS, Partners
Mar 02,2015
Teva Neuroscience & Access Health team up for special multiple sclerosis awareness show: thursday, 3/5
INforMS, MS Community, Partners
Feb 02,2015
Acorda announces data from first clinical trial of remyelinating antibody in multiple sclerosis
INforMS, Partners
Dec 03,2014
First multiple sclerosis patients in the U.S. receive Genzyme’s Lemtrada following FDA approval
INforMS, Partners
Nov 14,2014
Genzyme’s Lemtrada approved by the FDA
INforMS, Partners
Nov 04,2014
Genzyme announces enrollment of first patient in phase II Vatelizumab trial in RRMS
INforMS, MS Community, Partners
Oct 31,2014
Study on abnormal MRIs and the risk of developing multiple sclerosis featured in the IJMSC
Partners
Oct 27,2014
Optimizing multiple sclerosis management – new CME/CE courses for healthcare professionals
CMSC PR, Partners
Oct 20,2014
Results from two phase III studies added to U.S. label of Genzyme’s Aubagio
INforMS, Partners
Oct 01,2014
Employment in Multiple Sclerosis (MS) study
MS Community, Partners
Sep 21,2014
Novartis teams up with multiple sclerosis advocate David Osmond to launch Our Voice in Song
MS Community, Partners
Sep 11,2014
At four years, treatment effect maintained in patients who received Lemtrada in studies
INforMS, Partners
Sep 10,2014
New international survey finds multiple sclerosis patients and neurologists view communication positively
INforMS, MS Community, Partners
Aug 31,2014
IJMSC features article on the Multiple Sclerosis Self-Management Scale
Partners
Aug 24,2014
AIMS presents the latest on multiple sclerosis treatments
CMSC PR, Partners
Aug 15,2014
Biogen Idec’s PLEGRIDY approved in the US for the treatment of multiple sclerosis
INforMS, Partners
Jul 23,2014
PLEGRIDY (Peginterferon beta-1a) approved in the EU for the treatment of multiple sclerosis
INforMS, Partners
Jul 03,2014
Teva files citizen petition with the US FDA regarding the complexity of COPAXONE
INforMS, Partners
Jun 30,2014
Genzyme’s Lemtrada approved in Argentina for treatment of multiple sclerosis
INforMS, Partners
Jun 16,2014
Biogen Idec and AbbVie Announce Results from Phase 3 Study Investigating Daclizumab
INforMS, Partners
May 30,2014
Genzyme’s Lemtrada resubmission accepted for review by FDA
INforMS, Partners
May 30,2014
Data from Biogen Idec’s portfolio of multiple sclerosis therapies and pipeline featured at congresses
INforMS, Partners
May 28,2014
Biogen Idec announces official partnership with Sailing Sclerosis’ “Oceans of Hope”
INforMS, Partners
May 28,2014
EMD Serono data at CMSC & ACTRIMS Annual Meeting reinforces proven efficacy of rebif
CMSC PR, Partners
May 27,2014
Acorda Therapeutics to showcase online multiple sclerosis resources at 2014 CMSC/ACTRIMS meeting
CMSC PR, Partners
May 24,2014
Genzyme recognizes sixth annual World MS Day
INforMS, MS Community, Partners
May 23,2014
CHMP adopts positive opinion for PLEGRIDY as a treatment for multiple sclerosis in the EU
INforMS, Partners
May 08,2014
Teva announces COPAXONE recognized as “Brand of the Year” by Pharm Exec Magazine
INforMS, Partners
May 01,2014
New TYSABRI analysis shows improved walking speed in significant number of multiple sclerosis patients
INforMS, Partners
Apr 30,2014
New data reinforce efficacy of TECFIDERA in multiple sclerosis patients with high disease activity
INforMS, Partners
Apr 30,2014
A farewell tribute to Mike Robinson – President, National Multiple Sclerosis Society of Zimbabwe
Partners
Apr 30,2014
Slowing of brain atrophy sustained at three years in patients treated with Lemtrada
INforMS, Partners
Apr 30,2014
Genzyme announces multi-year multiple sclerosis research collaboration with academic medical center
INforMS, Partners
Apr 24,2014
Dr. T.J. ‘Jock’ Murray is a 2014 inductee to the Canadian Medical Hall of Fame
Partners
Apr 19,2014
Teva announces supreme court denial of request for interim relief to stay
INforMS, Partners
Apr 14,2014
Biogen Idec to present new clinical data at AAN Annual Meeting
INforMS, Partners
Apr 14,2014
New continuing education program helps distinguish between primary care needs & multiple sclerosis symptoms
CMSC PR, Partners

Comments are closed.

  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

Upcoming Testing Periods

WINTER 2024 TESTING PERIOD

Application Deadline: December 6th, 2023

First Day of Testing: Saturday, January 6th, 2024

Last Day of Testing: Saturday, January 20th, 2024

SUMMER 2024 TESTING PERIOD

Application Deadline: May 1st, 2024

First Day of Testing: Saturday, June 1st, 2024

Last Day of Testing: Saturday, June 15th, 2024

Resources

Visit PTC to download a PDF version of the Handbook. Candidates can also apply online.

For more information:

Professional Testing Corporation http://www.ptcny.com/

  • 212-356-0660
  • 1350 Broadway, 17th Floor, New York, NY 10018

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM